Will Democratic Congress Put Drug Industry in Crosshairs?
By Donna Young
Thursday, November 6, 2008
With the Democrats taking the White House and making big gains in the House and Senate Tuesday, congressional oversight of medical product safety will shift from the FDA to industry, and drug and device makers should be prepared to be in the crosshairs, said John Manthei, global co-chair of the health care and life sciences practice at the Washington law firm Latham & Watkins LLP. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.